Hologic, Inc. (NASDAQ:HOLX) Director Sally Crawford sold 13,257 shares of the stock in a transaction on Monday, September 17th. The shares were sold at an average price of $39.54, for a total transaction of $524,181.78. Following the sale, the director now directly owns 167,701 shares of the company’s stock, valued at approximately $6,630,897.54. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Hologic stock opened at $41.17 on Friday. The stock has a market capitalization of $11.14 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 2.01 and a beta of 0.65. The company has a quick ratio of 0.99, a current ratio of 1.29 and a debt-to-equity ratio of 1.12. Hologic, Inc. has a one year low of $35.10 and a one year high of $45.09.
Hologic (NASDAQ:HOLX) last announced its earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.02. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. The business had revenue of $824.00 million during the quarter, compared to the consensus estimate of $800.14 million. sell-side analysts anticipate that Hologic, Inc. will post 2.24 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of HOLX. Royal London Asset Management Ltd. purchased a new stake in Hologic in the second quarter valued at approximately $4,837,000. WINTON GROUP Ltd purchased a new stake in Hologic in the second quarter valued at approximately $5,837,000. Andra AP fonden purchased a new stake in Hologic in the 2nd quarter worth approximately $3,581,000. Amussen Hunsaker Associates LLC purchased a new stake in Hologic in the 2nd quarter worth approximately $159,000. Finally, Jane Street Group LLC boosted its position in Hologic by 595.7% in the 2nd quarter. Jane Street Group LLC now owns 48,029 shares of the medical equipment provider’s stock worth $1,909,000 after purchasing an additional 41,125 shares in the last quarter. Hedge funds and other institutional investors own 98.61% of the company’s stock.
Several research analysts have commented on HOLX shares. TheStreet upgraded shares of Hologic from a “c” rating to a “b” rating in a report on Tuesday, July 31st. Cowen restated a “buy” rating and set a $45.00 price objective on shares of Hologic in a research note on Wednesday, August 1st. Bank of America raised their price objective on shares of Hologic from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday, August 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a report on Wednesday, August 1st. Finally, Needham & Company LLC raised their price target on shares of Hologic from $43.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. Ten research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $44.47.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
See Also: Relative Strength Index
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.